A review of the preclinical development of dexrazoxane

Progress in Pediatric Cardiology

Volumn 36, Issue 1-2, 2014, Pages 33-38

  Herman, Eugene H ^a   Hasinoff, Brian B ^b   Steiner, Rudolf ^c   Lipshultz, Steven E ^d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardioprotection; Dexrazoxane; Doxorubicin; Experimental models; Extravasation; Mechanism

Indexed keywords

ALLOXAN; BLEOMYCIN; DAUNORUBICIN; DOXORUBICIN; OXYGEN; PARACETAMOL; RAZOXANE;

AREA UNDER THE CURVE; BIOCHEMISTRY; BIOLOGICAL ACTIVITY; CARDIOTOXICITY; CATALYSIS; CHEMISTRY; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; EXTRAVASATION; HEART PROTECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; IRON CHELATION; ISOLATED HEART; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 84926101316     PISSN: 10589813     EISSN: 15581519     Source Type: Journal    
DOI: 10.1016/j.ppedcard.2014.09.006     Document Type: Review

References (68)

1. Blum R.H., Carter S.K. Adriamycin: a new anticancer drug with significant clinical activity. Ann Intern Med 1974, 80:244-259.
2. Cortes E.P., Lutman G., Wanta J., Wallace J., Holland J. Adriamycin (NSC 123127) cardiotoxicity: a clinicopathologic correlation. Cancer Chemother Rep 1975, 6(part3):215-225.
3. Herman E.H., Ferrans V.J. Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity. Semin Oncol 1998, (Suppl. 10):15-21.
4. Herman E.H., Ferrans V.J. Animal models of anthracycline cardiotoxicity: basic mechanisms and cardioprotective activity. Prog Pediatr Cardiol 1998, 8:49-58.
5. Herman E.H., Ferrans V.J., Sanchez J. Methods of reducing anthracycline cardiotoxicity. Cancer Treatment and the Heart 1992, 114-169. Johns Hopkins Press, Baltimore. F. Muggia, M.D. Green, J. Speyer (Eds.).
6. Sterba M., Popelova O., Vavrova A., et al. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxid Redox Signal 2013, 18:899-929.
7. Lefrak E.A., Pitha J., Rosenheim S., Gottlieb J.A. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973, 32:302-314.
8. Herman E.H., Schein P., Farmer R.M. Comparative cardiac toxicity of daunomycin in three rodent species. Proc Soc Exp Biol Med 1970, 130:1098-1102.
9. Herman E.H., Vick J.A. The acute pharmacological actions of daunomycin in the dog and monkey. Pharmacology 1970, 3:291-304.
10. Burka B., Herman E., Vick J. Role of the sympathetic nervous system in daunomycin-induced arrhythmia in the monkey. Br J Pharmacol 1970, 39:501-510.
11. Vick J.A., Herman E.H. An isolated dog or monkey heart preparation for studying cardioactive compounds. Pharmacology 1971, 6:290-299.
12. Herman E.H., Mhatre R.M., Lee I.P., Waravdekar V.S. Prevention of the cardiotoxic effects of adriamycin and daunomycin in the isolated dog heart. Proc Soc Exp Biol Med 1972, 140:234-239.
13. Herman E.H., El-Hage A.N., Ferrans V.J., Witiak D.T. Reduction by ICRF-187 of acute daunorubicin toxicity in Syrian golden hamsters. Res Commun Pathol Pharmacol 1983, 40:217-231.
14. Herman E.H., Ferrans V.J., Jordan W., Ardalan B. Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits. Res Commun Chem Pathol Pharmacol 1981, 31:85-97.
15. Herman E.H., Ferrans V.J. Pretreatment with ICRF-187 provides long lasting protection against chronic daunorubicin cardiotoxicity in rabbits. Cancer Chemother Pharmacol 1986, 16:102-106.
16. Herman E.H., Ferrans V.J. Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (+/-)-1,2-bis(3,5-dioxopiperazynl-1-propane (ICRF-187). Cancer Res 1981, 41:3436-3440.
17. Herman E.H., El-Hage A.N., Ferrans V.J., Ardalan B. Comparison of the severity of the chronic cardiac cardiotoxicity produced by doxorubicin in normotensive and hypertensive rats. Toxicol Appl Parmacol 1983, 78:202-214.
18. Herman E.H., El-Hage A.N., Ferrans V.J. Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats. Toxicol Appl Pharmacol 1988, 92:42-53.
19. Herman E.H., Ferrans V.J. Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity. Cancer Chemother Pharmacol 1993, 32:445-449.
20. Herman E.H., Ferrans V.J., Young R.S., Hamlin R.L. Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs. Cancer Res 1988, 48:6918-6925.
21. Speyer J.L., Green M.D., Kramer E., et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiotoxicity in women with advanced breast cancer. New Engl J Med 1988, 319:745-752.
22. Lipshultz S.E., Scully R.E., Lipsitz S.R., et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long term follow-up. Lancet Oncol 2010, 11:950-961.
23. Doroshow J.H. Dexrazoxane for the prevention of cardiac toxicity and treatment of extravasation injury from the anthracycline antibiotics. Curr Pharm Biotechnol 2012, 13:1949-1956.
24. Herman E.H., Lipshultz S.E., Rifai N., et al. Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity. Cancer Res 1998, 58:1995-1997.
25. Herman E.H., Zhang J., Lipshultz S.E., et al. Correlation between the serum levels of cardiac troponin T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 1999, 17:2237-2243.
26. Langer S.W., Sehested M., Jensen P.B. Treatment of anthracycline extravasation with dexrazoxane. Clin Cancer Res 2000, 6:3680-3686.
27. Razoxane and Dexrazoxane-Two Multifunctional Agents: Experimental and Clinical Results 2010, Springer Science+Business Media B.V., Springer Dordrecht, London. K. Hellmann, W. Rhomberg (Eds.).
28. Mouridsen H.T., Langer S.W., Buter J., et al. Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Ann Oncol 2007, 18:546-550.
29. Hasinoff B.B. The use of dexrazoxane for the prevention of anthracycline extravasation injury. Expert Opin Investig Drugs 2008, 17:217-223.
30. El Hage A., Herman E.H., Yang G.C., Crouch R.K., Ferrans V.J. Mechanism of the protective activity of ICRF-187 against alloxan-induced diabetes in mice. Res Commun Pathol Pharmacol 1986, 52:341-360.
31. El-Hage A.N., Herman E.H., Ferrans V.J. Examination of the protective effect of ICRF-187 and dimethyl sulfoxide against acetaminophen-induced hepatotoxicity in Syrian golden hamsters. Toxicology 1983, 28:295-303.
32. Fukuda Y., Herman E.H., Ferrans V.J. Effect of ICRF-187 on the pulmonary damage induced by hypoxia in the rat. Toxicology 1992, 74:186-202.
33. Herman E.H., Hasinoff B.B., Zhang J., et al. Morphologic and morphometric evaluation of the effect of ICRF-187 on bleomycin-induced pulmonary toxicity. Toxicology 1995, 98:163-175.
34. Hasinoff B.B., Herman E.H. Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?. Cardiovasc Toxicol 2007, 7:140-144.
35. Hasinoff B.B. The pharmacology of dexrazoxane: iron chelating prodrug and topoisomerase II inhibitor. Razoxane and Dexrazoxane-Two Multifunctional Agents 2010, 158-167. Springer, Dordrecht. K. Hellmann, W. Rhomberg (Eds.).
36. Hasinoff B.B. The use of dexrazoxane for the prevention of anthracycline extravasation injury. Expert Opin Investig Drugs 2008, 17:217-223.
37. Hasinoff B.B., Kuschak T.I., Yalowich J.C., Creighton A.M. A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane). Biochem Pharmacol 1995, 50:953-958.
38. Shapiro A.B., Austin C.A. A high-throughput fluorescence anisotropy-based assay for human topoisomerase II beta-catalyzed ATP-dependent supercoiled DNA relaxation. Anal Biochem 2014, 448:23-29.
39. Hasinoff B.B., Hellmann K., Herman E.H., Ferrans V.J. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem 1998, 5:1-28.
40. Lyu Y.L., Kerrigan J.E., Lin C.P., et al. Topoisomerase IIβ mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res 2007, 67:8839-8846.
41. Vejpongsa P., Yeh E.T. Topoisomerase 2β: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity. Clin Pharmacol Ther 2014, 95:45-52.
42. Zhang S., Liu X., Bawa-Khalfe T., et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012, 18:1639-1642.
43. Dawson K.M. Studies on the stability and cellular distribution of dioxopiperazines in cultured BHK-21S cells. Biochem Pharmacol 1975, 24:2249-2253.
44. Diop N.K., Vitellaro L.K., Arnold P., Shang M., Marusak R.A. Iron complexes of the cardioprotective agent dexrazoxane (ICRF-187) and its desmethyl derivative, ICRF-154: solid state structure, solution thermodynamics, and DNA cleavage activity. J Inorg Biochem 2000, 78:209-216.
45. Hasinoff B.B., Schroeder P.E., Patel D. The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity. Mol Pharmacol 2003, 64:670-678.
46. Hasinoff B.B. Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage. Cardiovasc Toxicol 2002, 2:111-118.
47. Buss J.L., Hasinoff B.B. The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes. Agents Actions 1993, 40:86-95.
48. Fortune J.M., Osheroff N. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol 2000, 64:221-253.
49. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999, 57:727-741.
50. Pommier Y., Leo E., Zhang H., Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 2010, 17:421-433.
51. Swift L.M., Sarvazyan N. Localization of dichlorofluorescein in cardiac myocytes: implications for assessment of oxidative stress. Am J Physiol Heart Circ Physiol 2000, 278:H982-H990.
52. Hasinoff B.B., Schnabl K.L., Marusak R.A., Patel D., Huebner E. Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria. Cardiovasc Toxicol 2003, 3:89-99.
53. Sarvazyan N. Visualization of doxorubicin-induced oxidative stress in isolated cardiac myocytes. Am J Physiol 1996, 271:H2079-H2085.
54. Malisza K.L., Hasinoff B.B. Hydroxyl radical production by the iron complex of the hydrolysis product of the antioxidant cardioprotective agent ICRF-187 (dexrazoxane). Redox Rep 1996, 2:69-73.
55. Schroeder P.E., Jensen P.B., Sehested M., Hofland K.F., Langer S.W., Hasinoff B.B. Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide. Cancer Chemother Pharmacol 2003, 52:167-174.
56. Schroeder P.E., Davidson J.N., Hasinoff B.B. Dihydroorotase catalyzes the ring-opening of the hydrolysis intermediates of the cardioprotective drug dexrazoxane (ICRF-187). Drug Metab Dispos 2002, 30:1431-1435.
57. Schroeder P.E., Wang G.Q., Burczynski F.J., Hasinoff B.B. Metabolism of the cardioprotective drug dexrazoxane and one of its metabolites by isolated rat myocytes, hepatocytes and by blood. Drug Metab Dispos 2005, 33:719-725.
58. Schroeder P.E., Hasinoff B.B. Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal chelating form in the rat. Drug Metab Dispos 2005, 33:1367-1372.
59. Schroeder P.E., Patel D., Hasinoff B.B. The dihydroorotase inhibitor 5-aminoorotic acid inhibits the metabolism in the rat of the cardioprotective drug dexrazoxane and its one-ring open metabolites. Drug Metab Dispos 2008, 36:1780-1785.
60. Deweese J.E., Osheroff N. The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing. Nucleic Acids Res 2009, 37:738-748.
61. Nitiss J.L. Targeting DNA, topoisomerase II in cancer chemotherapy. Nat Rev Cancer 2009, 9:338-350.
62. Classen S., Olland S., Berger J.M. Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proc Natl Acad Sci U S A 2003, 100:14510.
63. Classen S., Olland S., Berger J.M. Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proc Natl Acad Sci U S A 2003, 100:10629-10634.
64. Pommier Y., Marchand C. Interfacial inhibitors: targeting macromolecular complexes. Nat Rev Drug Discov 2012, 11:25-36.
65. Pommier Y. Drugging topoisomerases: lessons and challenges. ACS Chem Biol 2013, 8:82-95.
66. Swain S.M., Vici P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol 2004, 130:1-7.
67. Martin E., Thougaard A.V., Grauslund M., et al. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. Toxicology 2009, 255:72-79.
68. Herman E.H., El-Hage A.N., Creighton A.M., Witiak D.T., Ferrans V.J. Comparison of the protective effect of ICRF-187 and structurally related analogues against acute daunorubicin toxicity in Syrian golden hamsters. Res Commun Chem Pathol Pharmacol 1985, 48:39-55.